News & Updates

Individuals with severe insulin-resistant diabetes (SIRD) appear to have the lowest physical fitness compared with other diabetes subgroups despite similar endothelial function across all cohorts, a study has shown. Moreover, those with severe autoimmune diabetes (SAID) have the lowest cardiovascular risk within the first year following diagnosis relative to other clusters.

Geriatric patients with atrial fibrillation (AF) are at increased risk of blood clots that can lodge in the brain and cause fatal strokes. At a recent webinar, Professor Olivier Hanon, Head of Geriatrics Department in Broca Hospital, Paris, France, shared insights on how to optimally protect geriatric patients with AF, with a special focus on direct oral anticoagulants (DOACs), particularly rivaroxaban, for stroke prevention in AF.

A key focus in the management of atrial fibrillation (AF) in older patients is stroke prevention through oral anticoagulation. However, a significant proportion of older AF patients remain undercoagulated due to the perceived bleeding risk of oral anticoagulants (OACs). Dr Tan Vern Hsen, Senior Consultant, Department of Cardiology, Changi General Hospital, Singapore, and Dr Barbara Helen Rosario, Senior Consultant, Department of Geriatric Medicine, Changi General Hospital, Singapore, shared their respective insights into managing older AF patients for an integrated approach.

Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.

Trastuzumab deruxtecan (T-DXd) reduces the risk of disease progression or death by 72 percent vs trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer whose disease progressed during or after treatment with an anti–HER-2 antibody, the first interim analysis of the DESTINY-Breast03 trial has shown.